Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections

Twelve patients were treated with omadacycline (OMC) as part of a multidrug regimen for Mycobacterium abscessus. The majority of infections were of pulmonary origin (7/12; 58.3%). The median (interquartile range) duration of OMC was 6.2 (4.2–11.0) months. Clinical success occurred in 9/12 (75.0%) pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Morrisette, Taylor, Alosaimy, Sara, Philley, Julie V, Wadle, Carly, Howard, Catessa, Webb, Andrew J, Veve, Michael P, Barger, Melissa L, Bouchard, Jeannette, Gore, Tristan W, Lagnf, Abdalhamid M, Ansari, Iman, Mejia-Chew, Carlos, Cohen, Keira A, Rybak, Michael J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890947/
https://www.ncbi.nlm.nih.gov/pubmed/33628856
http://dx.doi.org/10.1093/ofid/ofab002
Descripción
Sumario:Twelve patients were treated with omadacycline (OMC) as part of a multidrug regimen for Mycobacterium abscessus. The majority of infections were of pulmonary origin (7/12; 58.3%). The median (interquartile range) duration of OMC was 6.2 (4.2–11.0) months. Clinical success occurred in 9/12 (75.0%) patients. Three patients experienced a possible adverse effect while on therapy.

Ejemplares similares